Galmed Pharmaceuticals Ltd.
(NASDAQ : GLMD)

( )
GLMD PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
Loading GLMD News...
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc.
1.84%14.1614.2%$222.36m
SHPGShire PLC Sponsored ADR
0.49%148.440.4%$213.37m
PRGOPerrigo Co. Plc
1.84%79.206.4%$155.33m
MNKMallinckrodt Plc
0.87%35.9417.7%$115.49m
UTHRUnited Therapeutics Corporation
1.76%132.0413.9%$88.84m
ALRAlere Inc.
0.22%49.602.7%$76.96m
JAZZJazz Pharmaceuticals Plc
0.53%147.402.2%$71.01m
ENDPEndo International Plc
6.88%8.708.9%$67.71m
PRXLPAREXEL International Corporation
0.05%87.767.9%$66.28m
ICPTIntercept Pharmaceuticals, Inc.
1.33%105.4722.1%$62.18m
HZNPHorizon Pharma plc
-0.42%11.897.6%$53.22m
MYOKMyoKardia, Inc.
5.69%42.703.0%$47.24m
NDRMNeuroDerm Ltd.
0.13%38.653.6%$46.13m
PTLAPortola Pharmaceuticals, Inc.
-0.56%54.708.9%$44.17m
MDCOMedicines Company
0.19%36.6622.3%$43.14m

Company Profile

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of Aramchol, a novel, once-daily, oral therapy for treating liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. The Aramchol is initially being developed for treating Non-Alcoholic Steato-hepatitis, or NASH, a chronic disease affecting a large population, for treating patients who also suffer from obesity and insulin resistance. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.